MedPath

Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants

Not Applicable
Completed
Conditions
Gestational Diabetes
Interventions
Behavioral: Intervention
Registration Number
NCT01809431
Lead Sponsor
University of North Carolina, Chapel Hill
Brief Summary

The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.

Detailed Description

Women who are diagnosed with gestational diabetes are at increased risk for developing prediabetes and type 2 diabetes. To date, there have been few interdisciplinary interventions that target predominantly ethnic minority low-income women diagnosed with gestational diabetes. Programs are needed that intervene in the prenatal period to teach women the importance of breastfeeding to improve metabolic control and infant health and continue after birth to promote improved nutrition and exercise patterns and weight loss. Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy. Trends in breastfeeding duration and intensity, maternal infant feeding behavior, infant growth trajectory (weight-for-length) will also be measured. A total of 100 African American, bilingual Hispanic, and non-Hispanic White women diagnosed with gestational diabetes will be inducted and randomized by site to either the experimental or wait-list control group. Data will be collected at Time 1 (Baseline at 22-36 weeks pregnant), Time 2 (6 weeks postpartum), Time 3 (4 months postpartum and completion of Phase I), Time 4 (7 months postpartum and completion of Phase II), and Time 5 (10 months postpartum and after 3 months on their own). Primary maternal outcomes will include fasting blood glucose and weight (BMI). Secondary maternal outcomes will include clinical outcomes (oral glucose tolerance test, insulin levels, Homeostasis Model Assessment calculation, Hemoglobin A1c, complete lipid panel, and blood pressure); adiposity (waist circumference, triceps and subscapular skin folds); health behaviors (Health Promoting Lifestyle Profile II, Adult Health Behavior Survey, and Accelerometry for 7 days); and self-efficacy (Eating Self-Efficacy, Exercise Self-Efficacy Scale, and Breastfeeding Self-Efficacy Scale). Infant outcomes will include data on weight status (weight-for-length) and breastfeeding (weeks until stopped breastfeeding, weeks exclusively breastfed, and intensity of breastfeeding). Data analysis will include analysis of field notes, post-intervention interviews, and recruitment and retention efforts. Linear mixed-effects random coefficients models will be constructed to measure the effects of the intervention compared to the wait-list control group. Increasing breastfeeding and decreasing overweight in postpartum women who were diagnosed with gestational diabetes may both improve maternal glucose homeostasis and weight and stabilize infant growth trajectory, reducing the burden of metabolic disease across two generations.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Women between 22-36 weeks of pregnancy who are diagnosed with GDM

  • A diagnosis of GDM during the current pregnancy by two or more 100g Oral Glucose Tolerance Test (OGTT) values exceeding established thresholds (fasting 95, 1h 180, 2h 155, 3h 140 mg/dL)

  • Age 18-45 years old

  • A pre-pregnancy body mass index > 25kg/m2

    • Ability to read and write in English
    • Willingness to consent for themselves and their infant
Read More
Exclusion Criteria
  • They have a A1c ≥ 6.5 mg/dL (Type 2 diabetes)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
interventionInterventionBreastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
Primary Outcome Measures
NameTimeMethod
fasting blood glucoseBaseline to 10 months postpartum

Change in fasting blood glucose in mothers

weight (body mass index)Baseline to 10 months postpartum

Change in weight (body mass index)in mothers

Secondary Outcome Measures
NameTimeMethod
homeostasis model assessmentBaseline to 10 months postpartum

Change in homeostasis model assessment calculation in mothers

blood pressureBaseline to 10 months postpartum

Change in blood pressure in mothers

infant weight statusBirth to 10 months

weight status (weight-for-length) in children

hemoglobin A1cBaseline to 10 months postpartum

Change in hemoglobin A1c in mothers

self-efficacyBaseline to 10 months postpartum

Change in self-efficacy in mothers

oral glucose tolerance testBaseline to 10 months postpartum

Change in oral glucose tolerance test in mothers

insulin levelsBaseline to 10 months postpartum

Change in insulin levels in mothers

adiposityBaseline to 10 months

Change in adiposity (waist circumference, triceps and subscapular skin folds)in mothers

complete lipid panelBaseline to 10 months postpartum

Change in complete lipid panel in mothers

health behaviorsBaseline to 10 months postpartum

Change in health behaviors (Health Promoting Lifestyle Profile II, Adult Health Behavior Survey, and Accelerometry for 7 days) in mothers

breastfeedingBirth to 10 months

Change in breastfeeding (weeks until stopped breastfeeding, weeks exclusively breastfed, and intensity of breastfeeding) in infants

Trial Locations

Locations (2)

UNC-Rex Health Care

🇺🇸

Raleigh, North Carolina, United States

WakeMed

🇺🇸

Raleigh, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath